Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 220
- Registration Number
- NCT02110303
- Locations
- 🇬🇧
Edinburgh Heart Centre, Edinburgh, Lothian, United Kingdom
Effect of Ticagrelor on Fractional Flow Reserve
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 76
- Registration Number
- NCT02108808
- Locations
- 🇬🇷
Patras University Hospital, Patras, Achaia, Greece
Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management
- Conditions
- Interventions
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Seung-Jung Park
- Target Recruit Count
- 800
- Registration Number
- NCT02094963
- Locations
- 🇰🇷
Dong-A Medical Center, Pusan, Korea, Republic of
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT02091921
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Catholic University of the Sacred Heart
- Target Recruit Count
- 55
- Registration Number
- NCT02071966
- Locations
- 🇮🇹
Policlinico "A.Gemelli", Rome, Italy
Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Hellenic Cardiovascular Research Society
- Target Recruit Count
- 120
- Registration Number
- NCT02071212
- Locations
- 🇬🇷
Ippokratio Hospital, Athens, Greece
The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 145
- Registration Number
- NCT02070653
- Locations
- 🇸🇪
Department of Surgical Sciences/Vascular Surgery, Uppsala University, Uppsala, Sweden
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 65
- Registration Number
- NCT02065479
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Boca Raton Regional Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT02053909
- Locations
- 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇨🇦University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT02052635
- Locations
- 🇺🇸
Research Site, Rapid City, South Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.